A5020320888- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Advanced Radiotherapy Techniques
- Pituitary Gland Disorders and Treatments
- Radiation Therapy and Dosimetry
- Adrenal and Paraganglionic Tumors
- Medical Imaging and Pathology Studies
- Glioma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Prostate Cancer Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Thyroid Cancer Diagnosis and Treatment
- Bone health and treatments
- Radiomics and Machine Learning in Medical Imaging
- Lymphoma Diagnosis and Treatment
- Chemical Reactions and Isotopes
- Monoclonal and Polyclonal Antibodies Research
- Effects of Radiation Exposure
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2018-2025
European Institute of Oncology
2009-2022
Weill Cornell Medicine
2020-2021
Kettering University
2017-2020
University of California, San Francisco
2020
Wren Laboratories (United States)
2014-2016
Ripamonti
2007-2014
University of Turin
2014
Erasmus MC
2014
Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation involving the systemic administration of radiolabelled peptide designed to target with high affinity and specificity receptors overexpressed on tumours. PRRNT employing radiotagged somatostatin agonists 90Y-DOTATOC ([90Y-DOTA0,Tyr3]-octreotide) or 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3,Thr8]-octreotide [177Lu-DOTA0,Tyr3]-octreotate) have been successfully used for past 15 years metastatic inoperable neuroendocrine...
The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria peptide receptor radionuclide therapy (PRRT) and defining the minimum requirements PRRT. It not guidelines' aim give recommendations on use specific radiolabelled somatostatin analogues PRRT as different are being used, their availability governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has...
Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10-20% of patients amenable to curative treatment, such as resection transplant. Liver metastases frequently caused by colorectal cancer, which accounts for second cancer-related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown be a safe effective treatment option. The vast potential...
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified PSMA PET imaging. Promising results PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations targeting molecules radiolabels. Definitive evidence safety efficacy [177Lu]Lu-PSMA-617 combination standard-of-care has demonstrated metastatic...
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific professional organization founded in 1954 to promote the science, technology, practical application nuclear medicine. Its 18,000 members are physicians, technologists, scientists specializing
Several authors reported the superiority of (68)Ga-DOTANOC PET/CT to conventional imaging (CI) for assessment neuroendocrine tumors (NET). However, detection a higher number lesions is not necessarily followed by modification disease stage or therapeutic approach. The aim this study was assess impact on clinical management NET patients.The included 90 patients with pathologic confirmation NET, CT performed within month PET/CT, and follow-up period at least 1 y. results were compared CI...